p38 MAP kinase inhibitors as potential therapeutic drugs for neural diseases

Central Nervous System Agents in Medicinal Chemistry

Volumn 11, Issue 1, 2011, Pages 45-59

  Yasuda, S ^a   Sugiura, H ^a   Tanaka, H ^a,b   Takigami, S ^a   Yamagata, K ^a,c  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c SHUKUTOKU UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Cytokine; Depression; Epilepsy; Ischemia; Neuropathic pain; p38 MAP kinase inhibitor; Synaptic plasticity

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; DILMAPIMOD; DORAMAPIMOD; LOSMAPIMOD; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MW 012069A SRM; SD 282; SEMAPIMOD; TALMAPIMOD; UNCLASSIFIED DRUG; VX 702; ENZYME INHIBITOR; IMIDAZOLE DERIVATIVE;

ALZHEIMER DISEASE; AMNESIA; BRAIN ISCHEMIA; DEPRESSION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EPILEPSY; HUMAN; MAJOR DEPRESSION; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NERVE CELL PLASTICITY; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NONHUMAN; PAIN; PARKINSON DISEASE; REVIEW; RHEUMATOID ARTHRITIS; SEIZURE; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; CLINICAL TRIAL (TOPIC); METABOLISM; NERVOUS SYSTEM DISEASES; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE;

CELL LINE; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; MAP KINASE SIGNALING SYSTEM; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NERVOUS SYSTEM DISEASES; NEURONAL PLASTICITY; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN STRUCTURE, TERTIARY;

EID: 79953008825     PISSN: 18715249     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152411794961040     Document Type: Review

References (158)

1. Lee, J.C.; Laydon, J.T.; McDonnell, P.C.; Gallagher, T.F.; Kumar, S.; Green, D.; McNulty, D.; Blumenthal, M.J.; Heys, J.R.; Landvatter, S.W. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature, 1994, 372 (6508), 739-746.
2. Peifer, C.; Wagner, G.; Laufer, S. New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase. Curr. Top. Med. Chem., 2006, 6(2), 113-149.
3. Biondi, R.M.; Nebreda, A.R. Signalling specificity of Ser/Thr protein kinases through docking-site-mediated interactions. Biochem. J., 2003, 372(Pt 1), 1-13.
4. Chang, C.I.; Xu, B.E.; Akella, R.; Cobb, M.H.; Goldsmith, E.J. Crystal structures of MAP kinase p38 complexed to the docking sites on its nuclear substrate MEF2A and activator MKK3b. Mol. Cell, 2002, 9(6), 1241-1249.
5. Enslen, H.; Davis, R.J. Regulation of MAP kinases by docking domains. Biol. Cell, 2001, 93(1-2), 5-14.
6. Enslen, H.; Brancho, D.M.; Davis, R.J. Molecular determinants that mediate selective activation of p38 MAP kinase isoforms. EMBO J., 2000, 19(6), 1301-1311.
7. Weston, C.R.; Lambright, D.G.; Davis, R.J. Signal transduction. MAP kinase signaling specificity. Science, 2002, 296(5577), 2345-2347.
8. Kyriakis, J.M.; Avruch, J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev., 2001, 81(2), 807-869.
9. Han, J.; Lee, J.D.; Bibbs, L.; Ulevitch, R. J. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science, 1994, 265(5173), 808-811.
10. Brewster, J.L.; de Valoir, T.; Dwyer, N.D.; Winter, E.; Gustin, M.C. An osmosensing signal transduction pathway in yeast. Science, 1993, 259(5102), 1760-1763.
11. Rouse, J.; Cohen, P.; Trigon, S.; Morange, M.; Alonso-Llamazares, A.; Zamanillo, D.; Hunt, T.; Nebreda, A. R. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell, 1994, 78(6), 1027-1037.
12. Freshney, N.W.; Rawlinson, L.; Guesdon, F.; Jones, E.; Cowley, S.; Hsuan, J.; Saklatvala, J. Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell, 1994, 78(6), 1039-1049.
13. Jiang, Y.; Chen, C.; Li, Z.; Guo, W.; Gegner, J. A.; Lin, S.; Han, J. Characterization of the structure and function of a new mitogenactivated protein kinase (p38beta). J. Biol. Chem., 1996, 271(30), 17920-17926.
14. Lechner, C.; Zahalka, M.A.; Giot, J.F.; Moller, N.P.; Ullrich, A. ERK6, a mitogen-activated protein kinase involved in C2C12 myoblast differentiation. Proc. Natl. Acad. Sci. USA, 1996, 93(9), 4355-4359.
15. Mertens, S.; Craxton, M.; Goedert, M. SAP kinase-3, a new member of the family of mammalian stress-activated protein kinases. FEBS Lett., 1996, 383(3), 273-276.
16. Goedert, M.; Cuenda, A.; Craxton, M.; Jakes, R.; Cohen, P. Activation of the novel stress-activated protein kinase SAPK4 by cytokines and cellular stresses is mediated by SKK3 (MKK6); comparison of its substrate specificity with that of other SAP kinases. EMBO J., 1997, 16(12), 3563-3571.
17. Jiang, Y.; Gram, H.; Zhao, M.; New, L.; Gu, J.; Feng, L.; Di Padova, F.; Ulevitch, R. J.; Han, J. Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38delta. J. Biol. Chem., 1997, 272(48), 30122-30128.
18. Cuenda, A.; Rousseau, S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim. Biophys. Acta, 2007, 1773(8), 1358-1375.
19. Cuenda, A.; Rouse, J.; Doza, Y.N.; Meier, R.; Cohen, P.; Gallagher, T.F.; Young, P.R.; Lee, J.C. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett., 1995, 364(2), 229-233.
20. Stokoe, D.; Campbell, D.G.; Nakielny, S.; Hidaka, H.; Leevers, S. J.; Marshall, C.; Cohen, P. MAPKAP kinase-2; a novel protein kinase activated by mitogen-activated protein kinase. EMBO J., 1992, 11(11), 3985-3994.
21. Kuma, Y.; Campbell, D.G.; Cuenda, A. Identification of glycogen synthase as a new substrate for stress-activated protein kinase 2b/p38beta. Biochem. J., 2004, 379(Pt 1), 133-139.
22. Hudmon, A.; Choi, J. S.; Tyrrell, L.; Black, J. A.; Rush, A. M.; Waxman, S. G.; Dib-Hajj, S.D. Phosphorylation of sodium channel Na(v)1.8 by p38 mitogen-activated protein kinase increases current density in dorsal root ganglion neurons. J. Neurosci., 2008, 28(12), 3190-3201.
23. Bolshakov, V.Y.; Carboni, L.; Cobb, M.H.; Siegelbaum, S.A.; Belardetti, F. Dual MAP kinase pathways mediate opposing forms of long-term plasticity at CA3-CA1 synapses. Nat. Neurosci., 2000, 3(11), 1107-1112.
24. Rush, A.M.; Wu, J.; Rowan, M.J.; Anwyl, R. Group I metabotropic glutamate receptor (mGluR)-dependent long-term depression mediated via p38 mitogen-activated protein kinase is inhibited by previous high-frequency stimulation and activation of mGluRs and protein kinase C in the rat dentate gyrus in vitro. J. Neurosci., 2002, 22(14), 6121-6128.
25. Huang, C.C.; You, J.L.; Wu, M.Y.; Hsu, K.S. Rap1-induced p38 mitogen-activated protein kinase activation facilitates AMPA receptor trafficking via the GDI.Rab5 complex. Potential role in (S)-3,5-dihydroxyphenylglycene-induced long term depression. J. Biol. Chem., 2004, 279(13), 12286-12292.
26. Zhu, J.J.; Qin, Y.; Zhao, M.; Van Aelst, L.; Malinow, R. Ras and Rap control AMPA receptor trafficking during synaptic plasticity. Cell, 2002, 110(4), 443-455.
27. Izumi, Y.; Tokuda, K.; Zorumski, C.F. Long-term potentiation inhibition by low-level N-methyl-D-aspartate receptor activation involves calcineurin, nitric oxide, and p38 mitogen-activated protein kinase. Hippocampus, 2008, 18(3), 258-265.
28. Hsieh, H.; Boehm, J.; Sato, C.; Iwatsubo, T.; Tomita, T.; Sisodia, S.; Malinow, R. AMPAR removal underlies A[beta]-induced synaptic depression and dendritic spine loss. Neuron, 2006, 52,(5), 831-843.
29. Empson, R.M.; Buckby, L.E.; Kraus, M.; Bates, K.J.; Crompton, M.R.; Gundelfinge, E.D.; Beesley, R.P.W. The cell adhesion molecule neuroplastin-65 inhibits hippocampal long-term potentiation via a mitogen-activated protein kinase p38-dependent reduction in surface expression of GluR1-containing glutamate receptors. J. Neurochem., 2006, 99(3), 850-860.
30. Butler, M.P.; O'Connor, J.J.; Moynagh, P.N. Dissection of tumornecrosis factor-[alpha] inhibition of long-term potentiation (LTP) reveals a p38 mitogen-activated protein kinase-dependent mechanism which maps to early--but not late--phase LTP. Neuroscience, 2004, 124(2), 319-326.
31. Matsuzaki, M.; Honkura, N.; Ellis-Davies, G. C.; Kasai, H. Structural basis of long-term potentiation in single dendritic spines. Nature, 2004, 429(6993), 761-766.
32. Engert, F.; Bonhoeffer, T. Dendritic spine changes associated with hippocampal long-term synaptic plasticity. Nature, 1999, 399(6731), 66-70.
33. Nagerl, U.V.; Eberhorn, N.; Cambridge, S.B.; Bonhoeffer, T. Bidirectional activity-dependent morphological plasticity in hippocampal neurons. Neuron, 2004, 44(5), 759-767.
34. Zhou, Q.; Homma, K.J.; Poo, M.M. Shrinkage of dendritic spines associated with long-term depression of hippocampal synapses. Neuron, 2004, 44(5), 749-757.
35. Passafaro, M.; Piech, V.; Sheng, M. Subunit-specific temporal and spatial patterns of AMPA receptor exocytosis in hippocampal neurons. Nat. Neurosci., 2001, 4(9), 917-926.
36. Lee, S.H.; Liu, L.; Wang, Y.T.; Sheng, M. Clathrin adaptor AP2 and NSF interact with overlapping sites of GluR2 and play distinct roles in AMPA receptor trafficking and hippocampal LTD. Neuron, 2002, 36(4), 661-674.
37. Lee, S.H.; Simonetta, A.; Sheng, M. Subunit rules governing the sorting of internalized AMPA receptors in hippocampal neurons. Neuron, 2004, 43(2), 221-236.
38. Passafaro, M.; Nakagawa, T.; Sala, C.; Sheng, M. Induction of dendritic spines by an extracellular domain of AMPA receptor subunit GluR2. Nature, 2003, 424(6949), 677-681.
39. Saglietti, L.; Dequidt, C.; Kamieniarz, K.; Rousset, M.-C.; Valnegri, P.; Thoumine, O.; Beretta, F.; Fagni, L.; Choquet, D.; Sala, C.; Sheng, M.; Passafaro, M. Extracellular interactions between GluR2 and N-cadherin in spine regulation. Neuron, 2007, 54(3), 461-477.
40. Hoppe, C.; Elger, C.E.; Helmstaedter, C. Long-term memory impairment in patients with focal epilepsy. Epilepsia, 2007, 48(Suppl) 9, 26-29.
41. Mizrahi, A.; Crowley, J.C.; Shtoyerman, E.; Katz, L.C. Highresolution in vivo imaging of hippocampal dendrites and spines. J. Neurosci., 2004, 24(13), 3147-3151.
42. Yamagata, K.; Andreasson, K. I.; Sugiura, H.; Maru, E.; Dominique, M.; Irie, Y.; Miki, N.; Hayashi, Y.; Yoshioka, M.; Kaneko, K.; Kato, H.; Worley, P. F. Arcadlin is a neural activity-regulated cadherin involved in long term potentiation. J. Biol. Chem., 1999, 274(27), 19473-19479.
43. Yamamoto, A.; Amacher, S.L.; Kim, S.H.; Geissert, D.; Kimmel, C.B.; De Robertis, E M. Zebrafish paraxial protocadherin is a downstream target of spadetail involved in morphogenesis of gastrula mesoderm. Development, 1998, 125(17), 3389-3397.
44. Yasuda, S.; Tanaka, H.; Sugiura, H.; Okamura, K.; Sakaguchi, T.; Tran, U.; Takemiya, T.; Mizoguchi, A.; Yagita, Y.; Sakurai, T.; De Robertis, E.M.; Yamagata, K. Activity-induced protocadherin arcadlin regulates dendritic spine number by triggering N-cadherin endocytosis via TAO2beta and p38 MAP kinases. Neuron, 2007, 56(3), 456-471.
45. Togashi, H.; Abe, K.; Mizoguchi, A.; Takaoka, K.; Chisaka, O.; Takeichi, M. Cadherin regulates dendritic spine morphogenesis. Neuron, 2002, 35,(1), 77-89.
46. Sugiura, H.; Tanaka, H.; Yasuda, S.; Takemiya, T.; Yamagata, K. Transducing neuronal activity into dendritic spine morphology: new roles for p38 MAP kinase and N-cadherin. Neuroscientist, 2009, 15(1), 90-104.
47. Mehta, S.L.; Manhas, N.; Raghubir, R. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res. Rev., 2007, 54(1), 34-66.
48. Sugino, T.; Nozaki, K.; Hashimoto, N. Activation of mitogenactivated protein kinases in gerbil hippocampus with ischemic tolerance induced by 3-nitropropionic acid. Neurosci. Lett., 2000, 278(1-2), 101-104.
49. Alessandrini, A.; Namura, S.; Moskowitz, M.A.; Bonventre, J.V. MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia. Proc. Natl. Acad. Sci. USA, 1999, 96(22), 12866-12869.
50. Irving, E.A.; Bamford, M. Role of mitogen- and stress-activated kinases in ischemic injury. J. Cereb. Blood Flow Metab., 2002, 22(6), 631-647.
51. Xia, Z.; Dickens, M.; Raingeaud, J.; Davis, R. J.; Greenberg, M. E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science, 1995, 270(5240), 1326-1331.
52. Lee, J.C.; Young, P. R. Role of CSB/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. J. Leukoc. Biol., 1996, 59(2), 152-157.
53. Harada, J.; Sugimoto, M. An inhibitor of p38 and JNK MAP kinases prevents activation of caspase and apoptosis of cultured cerebellar granule neurons. Jpn. J. Pharmacol., 1999, 79(3), 369-378.
54. Barone, F.C.; Irving, E.A.; Ray, A.M.; Lee, J.C.; Kassis, S.; Kumar, S.; Badger, A.M.; Legos, J.J.; Erhardt, J.A.; Ohlstein, E.H.; Hunter, A.J.; Harrison, D.C.; Philpott, K.; Smith, B.R.; Adams, J.L.; Parsons, A.A. Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia. Med. Res. Rev., 2001, 21(2), 129-145.
55. Ikonomidou, C.; Price, M.T.; Mosinger, J.L.; Frierdich, G.; Labruyere, J.; Salles, K.S.; Olney, J.W., Hypobaric-ischemic conditions produce glutamate-like cytopathology in infant rat brain. J. Neurosci., 1989, 9(5), 1693-1700.
56. Hsu, M.; Buzsaki, G. Vulnerability of mossy fiber targets in the rat hippocampus to forebrain ischemia. J. Neurosci., 1993, 13(9), 3964-3979.
57. Matesic, D.F.; Lin, R.C. Microtubule-associated protein 2 as an early indicator of ischemia-induced neurodegeneration in the gerbil forebrain. J. Neurochem., 1994, 63(3), 1012-1020.
58. Gorter, J.A.; Petrozzino, J.J.; Aronica, E.M.; Rosenbaum, D.M.; Opitz, T.; Bennett, M.V.; Connor, J.A.; Zukin, R.S. Global ischemia induces downregulation of Glur2 mRNA and increases AMPA receptor-mediated Ca2+ influx in hippocampal CA1 neurons of gerbil. J. Neurosci., 1997, 17(16), 6179-6188.
59. Hasbani, M.J.; Schlief, M.L.; Fisher, D.A.; Goldberg, M.P. Dendritic spines lost during glutamate receptor activation reemerge at original sites of synaptic contact. J. Neurosci., 2001, 21(7), 2393-23403.
60. Sheng, J.G.; Jones, R.A.; Zhou, X.Q.; McGinness, J.M.; Van Eldik, L.J.; Mrak, R.E.; Griffin, W.S. Interleukin-1 promotion of MAPKp38 overexpression in experimental animals and in Alzheimer's disease: potential significance for tau protein phosphorylation. Neurochem. Int., 2001, 39(5-6), 341-348.
61. Ferrer, I.; Gomez-Isla, T.; Puig, B.; Freixes, M.; Ribe, E.; Dalfo, E.; Avila, J. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr. Alzheimer. Res., 2005, 2(1), 3-18.
62. Hensley, K.; Floyd, R.A.; Zheng, N.Y.; Nael, R.; Robinson, K.A.; Nguyen, X.; Pye, Q.N.; Stewart, C.A.; Geddes, J.; Markesbery, W.R.; Patel, E.; Johnson, G.V.; Bing, G. p38 kinase is activated in the Alzheimer's disease brain. J. Neurochem., 1999, 72(5), 2053-2058.
63. Pei, J.J.; Braak, E.; Braak, H.; Grundke-Iqbal, I.; Iqbal, K.; Winblad, B.; Cowburn, R.F. Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration. J. Alzheimers Dis., 2001, 3(1), 41-48.
64. Sun, A.; Liu, M.; Nguyen, X.V.; Bing, G. P38 MAP kinase is activated at early stages in Alzheimer's disease brain. Exp. Neurol., 2003, 183(2), 394-405.
65. Zhu, X.; Rottkamp, C.A.; Boux, H.; Takeda, A.; Perry, G.; Smith, M.A. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J. Neuropathol. Exp. Neurol., 2000, 59(10), 880-888.
66. Zhu, X.; Rottkamp, C.A.; Hartzler, A.; Sun, Z.; Takeda, A.; Boux, H.; Shimohama, S.; Perry, G.; Smith, M. A. Activation of MKK6, an upstream activator of p38, in Alzheimer's disease. J. Neurochem., 2001, 79(2), 311-318.
67. Culbert, A.A.; Skaper, S.D.; Howlett, D.R.; Evans, N.A.; Facci, L.; Soden, P. E.; Seymour, Z.M.; Guillot, F.; Gaestel, M.; Richardson, J.C. MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease. J. Biol. Chem., 2006, 281(33), 23658-23667.
68. Ferrer, I.; Boada Rovira, M.; Sanchez Guerra, M.L.; Rey, M.J.; Costa-Jussa, F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol., 2004, 14(1), 11-20.
69. Giovannini, M.G.; Scali, C.; Prosperi, C.; Bellucci, A.; Vannucchi, M.G.; Rosi, S.; Pepeu, G.; Casamenti, F. Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol. Dis., 2002, 11(2), 257-274.
70. Savage, M.J.; Lin, Y.G.; Ciallella, J.R.; Flood, D.G.; Scott, R.W. Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. J. Neurosci., 2002, 22(9), 3376-3385.
71. Lee, V.M.; Goedert, M.; Trojanowski, J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci., 2001, 24, 1121-1159.
72. Kar, S.; Fan, J.; Smith, M. J.; Goedert, M.; Amos, L. A., Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. EMBO J., 2003, 22(1), 70-77.
73. Bramblett, G. T.; Goedert, M.; Jakes, R.; Merrick, S. E.; Trojanowski, J. Q.; Lee, V. M. Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron, 1993, 10(6), 1089-1099.
74. Goedert, M. The significance of tau and alpha-synuclein inclusions in neurodegenerative diseases. Curr. Opin. Genet. Dev., 2001, 11(3), 343-351.
75. Yoshida, H.; Ihara, Y. Tau in paired helical filaments is functionally distinct from fetal tau: assembly incompetence of paired helical filament-tau. J. Neurochem., 1993, 61(3), 1183-1186.
76. Feijoo, C.; Campbell, D.G.; Jakes, R.; Goedert, M.; Cuenda, A. Evidence that phosphorylation of the microtubule-associated protein Tau by SAPK4/p38delta at Thr50 promotes microtubule assembly. J. Cell. Sci., 2005, 118(Pt 2), 397-408.
77. Atzori, C.; Ghetti, B.; Piva, R.; Srinivasan, A.N.; Zolo, P.; Delisle, M.B.; Mirra, S.S.; Migheli, A. Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. J. Neuropathol. Exp. Neurol., 2001, 60(12), 1190-1197.
78. Ferrer, I.; Blanco, R.; Carmona, M.; Puig, B.; Barrachina, M.; Gomez, C.; Ambrosio, S. Active, phosphorylation-dependent mitogen- activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies. J. Neural. Transm., 2001, 108(12), 1383-1396.
79. Goedert, M.; Hasegawa, M.; Jakes, R.; Lawler, S.; Cuenda, A.; Cohen, P. Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases. FEBS Lett., 1997, 409(1), 57-62.
80. Buee-Scherrer, V.; Goedert, M. Phosphorylation of microtubuleassociated protein tau by stress-activated protein kinases in intact cells. FEBS Lett., 2002, 515(1-3), 151-154.
81. Jenkins, S.M.; Zinnerman, M.; Garner, C.; Johnson, G. V. Modulation of tau phosphorylation and intracellular localization by cellular stress. Biochem. J., 2000, 345, 263-270.
82. Franciosi, S.; Ryu, J.K.; Choi, H.B.; Radov, L.; Kim, S.U.; McLarnon, J.G. Broad-spectrum effects of 4-aminopyridine to modulate amyloid beta1-42-induced cell signaling and functional responses in human microglia. J. Neurosci., 2006, 26(45), 11652-11664.
83. Kim, S.H.; Smith, C.J.; Van Eldik, L.J. Importance of MAPK pathways for microglial pro-inflammatory cytokine IL-1 beta production. Neurobiol. Aging, 2004, 25(4), 431-439.
84. Koistinaho, M.; Kettunen, M.I.; Goldsteins, G.; Keinanen, R.; Salminen, A.; Ort, M.; Bures, J.; Liu, D.; Kauppinen, R.A.; Higgins, L.S.; Koistinaho, J. Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: role of inflammation. Proc. Natl. Acad. Sci. USA, 2002, 99(3), 1610-1615.
85. McDonald, D.R.; Bamberger, M.E.; Combs, C.K.; Landreth, G.E. beta-Amyloid fibrils activate parallel mitogen-activated protein kinase pathways in microglia and THP1 monocytes. J. Neurosci., 1998, 18(12), 4451-4460.
86. Pyo, H.; Jou, I.; Jung, S.; Hong, S.; Joe, E.H. Mitogen-activated protein kinases activated by lipopolysaccharide and beta-amyloid in cultured rat microglia. Neuroreport, 1998, 9(5), 871-874.
87. Lee, Y. B.; Schrader, J. W.; Kim, S.U. p38 map kinase regulates TNF-alpha production in human astrocytes and microglia by multiple mechanisms. Cytokine, 2000, 12(7), 874-880.
88. Bhat, N.R.; Zhang, P.; Lee, J.C.; Hogan, E.L. Extracellular signalregulated kinase and p38 subgroups of mitogen-activated protein kinases regulate inducible nitric oxide synthase and tumor necrosis factor-alpha gene expression in endotoxin-stimulated primary glial cultures. J. Neurosci., 1998, 18(5), 1633-1641.
89. Li, Y.; Liu, L.; Barger, S.W.; Griffin, W. S. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J. Neurosci., 2003, 23(5), 1605-1611.
90. Symons, A.; Beinke, S.; Ley, S.C. MAP kinase kinase kinases and innate immunity. Trends Immunol., 2006, 27(1), 40-48.
91. Kim, I.J.; Beck, H.N.; Lein, P.J.; Higgins, D. Interferon gamma induces retrograde dendritic retraction and inhibits synapse formation. J. Neurosci., 2002, 22(11), 4530-4539.
92. He, P.; Zhong, Z.; Lindholm, K.; Berning, L.; Lee, W.; Lemere, C.; Staufenbiel, M.; Li, R.; Shen, Y. Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. J. Cell Biol., 2007, 178(5), 829-841.
93. Quinn, N. P. Classification of fluctuations in patients with Parkinson's disease. Neurology, 1998, 51(2 Suppl 2), S25-S29.
94. Przedborski, S.; Jackson-Lewis, V.; Djaldetti, R.; Liberatore, G.; Vila, M.; Vukosavic, S.; Almer, G. The parkinsonian toxin MPTP: action and mechanism. Restor. Neurol. Neurosci., 2000, 16(2), 135-142.
95. Du, Y.; Ma, Z.; Lin, S.; Dodel, R.C.; Gao, F.; Bales, K.R.; Triarhou, L.C.; Chernet, E.; Perry, K.W.; Nelson, D.L.; Luecke, S.; Phebus, L.A.; Bymaster, F.P.; Paul, S.M. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. USA, 2001, 98(25), 14669-14674.
96. Lee, D.Y.; Oh, Y.J.; Jin, B.K. Thrombin-activated microglia contribute to death of dopaminergic neurons in rat mesencephalic cultures: dual roles of mitogen-activated protein kinase signaling pathways. Glia, 2005, 51(2), 98-110.
97. Onyango, I.G.; Tuttle, J.B.; Bennett, J.P., Jr. Activation of p38 and N-acetylcysteine-sensitive c-Jun NH2-terminal kinase signaling cascades is required for induction of apoptosis in Parkinson's disease cybrids. Mol. Cell. Neurosci., 2005, 28(3), 452-461.
98. Plun-Favreau, H.; Klupsch, K.; Moisoi, N.; Gandhi, S.; Kjaer, S.; Frith, D.; Harvey, K.; Deas, E.; Harvey, R.J.; McDonald, N.; Wood, N.W.; Martins, L.M.; Downward, J. The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nat. Cell. Biol., 2007, 9(11), 1243-1252.
99. Hasegawa, T.; Treis, A.; Patenge, N.; Fiesel, F.C.; Springer, W.; Kahle, P.J., Parkin protects against tyrosinase-mediated dopamine neurotoxicity by suppressing stress-activated protein kinase pathways. J. Neurochem., 2008, 105(5), 1700-1715.
100. Kitada, T.; Asakawa, S.; Hattori, N.; Matsumine, H.; Yamamura, Y.; Minoshima, S.; Yokochi, M.; Mizuno, Y.; Shimizu, N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 1998, 392(6676), 605-608.
101. Trapp, B.D.; Nave, K.-A. Multiple Sclerosis: An Immune or Neurodegenerative Disorder? Ann. Rev. Neurosci., 2008, 31(1), 247-269.
102. Noseworthy, J.H.; Lucchinetti, C.; Rodriguez, M.; Weinshenker, B.G. Multiple sclerosis. N. Engl. J. Med., 2000, 343(13), 938-952.
103. Lindert, R.B.; Haase, C.G.; Brehm, U.; Linington, C.; Wekerle, H.; Hohlfeld, R., Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein. Brain, 1999, 122(Pt 11), 2089-2100.
104. Sun, J.B.; Olsson, T.; Wang, W.Z.; Xiao, B.G.; Kostulas, V.; Fredrikson, S.; Ekre, H.P.; Link, H. Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur. J. Immunol., 1991, 21(6), 1461-1468.
105. Chu, N.R.; Wu, H.B.; Wu, T.; Boux, L.J.; Siegel, M.I.; Mizzen, L.A. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin. Exp. Immunol., 2000, 121(2), 216-225.
106. Zaheer, A.; Zaheer, S.; Sahu, S.K.; Knight, S.; Khosravi, H.; Mathur, S.N.; Lim, R., A novel role of glia maturation factor: induction of granulocyte-macrophage colony-stimulating factor and pro-inflammatory cytokines. J. Neurochem., 2007, 101(2), 364-376.
107. Selmaj, K.W.; Raine, C.S. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann. Neurol., 1988, 23(4), 339-346.
108. Akassoglou, K.; Bauer, J.; Kassiotis, G.; Pasparakis, M.; Lassmann, H.; Kollias, G.; Probert, L. Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy. Am. J. Pathol., 1998, 153(3), 801-813.
109. Ji, R. R. Mitogen-activated protein kinases as potential targets for pain killers. Curr. Opin. Investig. Drugs 2004, 5(1), 71-75.
110. Kehlet, H.; Jensen, T. S.; Woolf, C. J. Persistent postsurgical pain: risk factors and prevention. Lancet, 2006, 367(9522), 1618-1625.
111. Woolf, C.J.; Mannion, R.J. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet, 1999, 353(9168), 1959-1964.
112. Tsuda, M.; Shigemoto-Mogami, Y.; Koizumi, S.; Mizokoshi, A.; Kohsaka, S.; Salter, M.W.; Inoue, K. P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature, 2003, 424(6950), 778-783.
113. Khakh, B.S. Molecular physiology of P2X receptors and ATP signalling at synapses. Nat. Rev. Neurosci., 2001, 2(3), 165-174.
114. Ralevic, V.; Burnstock, G. Receptors for purines and pyrimidines. Pharmacol. Rev., 1998, 50(3), 413-492.
115. Beattie, E.C.; Stellwagen, D.; Morishita, W.; Bresnahan, J.C.; Ha, B.K.; Von Zastrow, M.; Beattie, M.S.; Malenka, R.C. Control of synaptic strength by glial TNFalpha. Science, 2002, 295(5563), 2282-2285.
116. Stellwagen, D.; Beattie, E.C.; Seo, J.Y.; Malenka, R.C. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J. Neurosci., 2005, 25(12), 3219-3228.
117. Harris, J.A.; Corsi, M.; Quartaroli, M.; Arban, R.; Bentivoglio, M. Upregulation of spinal glutamate receptors in chronic pain. Neuroscience, 1996, 74(1), 7-12.
118. Ji, R.R.; Kohno, T.; Moore, K.A.; Woolf, C.J. Central sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci., 2003, 26(12), 696-705.
119. Maier, S.F.; Watkins, L.R. Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol. Rev., 1998, 105(1), 83-107.
120. Dantzer, R.; O'Connor, J.C.; Freund, G.G.; Johnson, R.W.; Kelley, K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci., 2008, 9(1), 46-56.
121. Stone, E.A.; Lehmann, M. L.; Lin, Y.; Quartermain, D. Depressive behavior in mice due to immune stimulation is accompanied by reduced neural activity in brain regions involved in positively motivated behavior. Biol. Psychiatry, 2006, 60(8), 803-811.
122. Gold, P. W.; Loriaux, D.L.; Roy, A.; Kling, M.A.; Calabrese, J. R.; Kellner, C. H.; Nieman, L.K.; Post, R.M.; Pickar, D.; Gallucci, W.; et al. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications. N. Engl. J. Med., 1986, 314(21), 1329-1335.
123. Gold, P.W.; Chrousos, G.; Kellner, C.; Post, R.; Roy, A.; Augerinos, P.; Schulte, H.; Oldfield, E.; Loriaux, D.L. Psychiatric implications of basic and clinical studies with corticotropin-releasing factor. Am. J. Psychiatry, 1984, 141(5), 619-627.
124. Nemeroff, C.B.; Evans, D.L. Correlation between the dexamethasone suppression test in depressed patients and clinical response. Am. J. Psychiatry, 1984, 141(2), 247-249.
125. Chen, Y.; Dube, C.M.; Rice, C.J.; Baram, T.Z. Rapid loss of dendritic spines after stress involves derangement of spine dynamics by corticotropin-releasing hormone. J. Neurosci., 2008, 28(11), 2903-2911.
126. McEwen, B.S. Mood disorders and allostatic load. Biol. Psychiatry, 2003, 54(3), 200-207.
127. Sousa, N.; Lukoyanov, N.V.; Madeira, M.D.; Almeida, O.F.; Paula-Barbosa, M. M. Reorganization of the morphology of hippocampal neurites and synapses after stress-induced damage correlates with behavioral improvement. Neuroscience, 2000, 97(2), 253-266.
128. Gaestel, M.; Mengel, A.; Bothe, U.; Asadullah, K. Protein kinases as small molecule inhibitor targets in inflammation. Curr. Med. Chem., 2007, 14(21), 2214-2234.
129. Knight, Z.A.; Shokat, K.M. Features of selective kinase inhibitors. Chem. Biol. 2005, 12(6), 621-637.
130. Tong, L.; Pav, S.; White, D.M.; Rogers, S.; Crane, K.M.; Cywin, C.L.; Brown, M.L.; Pargellis, C.A. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat. Struct. Biol., 1997, 4(4), 311-316.
131. Wang, X.; Proud, C.G. p70 S6 kinase is activated by sodium arsenite in adult rat cardiomyocytes: roles for phosphatidylinositol 3- kinase and p38 MAP kinase. Biochem. Biophys. Res. Commun., 1997, 238(1), 207-212.
132. Bolos, J. Structure-activity relationships of p38 mitogen-activated protein kinase inhibitors. Mini. Rev. Med. Chem., 2005, 5(9), 857-868.
133. Adams, J.L.; Boehm, J.C.; Kassis, S.; Gorycki, P.D.; Webb, E.F.; Hall, R.; Sorenson, M.; Lee, J.C.; Ayrton, A.; Griswold, D.E.; Gallagher, T.F. Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. Bioorg. Med. Chem. Lett., 1998, 8(22), 3111-3116.
134. Boehm, J.C.; Smietana, J.M.; Sorenson, M.E.; Garigipati, R.S.; Gallagher, T. F.; Sheldrake, P.L.; Bradbeer, J.; Badger, A.M.; Laydon, J.T.; Lee, J.C.; Hillegass, L. M.; Griswold, D.E.; Breton, J.J.; Chabot-Fletcher, M.C.; Adams, J.L. 1-substituted 4-aryl-5- pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency. J. Med. Chem., 1996, 39(20), 3929-3937.
135. Gallagher, T.F.; Seibel, G.L.; Kassis, S.; Laydon, J.T.; Blumenthal, M.J.; Lee, J. C.; Lee, D.; Boehm, J.C.; Fier-Thompson, S.M.; Abt, J.W.; Soreson, M.E.; Smietana, J. M.; Hall, R.F.; Garigipati, R.S.; Bender, P.E.; Erhard, K.F.; Krog, A.J.; Hofmann, G. A.; Sheldrake, P.L.; McDonnell, P.C.; Kumar, S.; Young, P.R.; Adams, J.L. Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. Bioorg. Med. Chem., 1997, 5(1), 49-64.
136. Wilson, K. P.; McCaffrey, P. G.; Hsiao, K.; Pazhanisamy, S.; Galullo, V.; Bemis, G. W.; Fitzgibbon, M. J.; Caron, P. R.; Murcko, M. A.; Su, M. S. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem. Biol., 1997, 4(6), 423-431.
137. Adams, J.L.; Boehm, J.C.; Gallagher, T.F.; Kassis, S.; Webb, E.F.; Hall, R.; Sorenson, M.; Garigipati, R.; Griswold, D.E.; Lee, J.C. Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity. Bioorg. Med. Chem. Lett., 2001, 11(21), 2867-2870.
138. Underwood, D.C.; Osborn, R.R.; Bochnowicz, S.; Webb, E.F.; Rieman, D.J.; Lee, J.C.; Romanic, A.M.; Adams, J.L.; Hay, D.W.; Griswold, D.E. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am. J. Physiol. Lung Cell. Mol. Physiol., 2000, 279(5), L895-902.
139. Badger, A.M.; Griswold, D.E.; Kapadia, R.; Blake, S.; Swift, B. A.; Hoffman, S.J.; Stroup, G.B.; Webb, E.; Rieman, D.J.; Gowen, M.; Boehm, J.C.; Adams, J.L.; Lee, J.C. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum., 2000, 43(1), 175-183.
140. Badger, A.M.; Roshak, A.K.; Cook, M.N.; Newman-Tarr, T.M.; Swift, B.A.; Carlson, K.; Connor, J.R.; Lee, J.C.; Gowen, M.; Lark, M.W.; Kumar, S. Differential effects of SB 242235, a selective p38 mitogen-activated protein kinase inhibitor, on IL-1 treated bovine and human cartilage/chondrocyte cultures. Osteoarthritis Cartilage, 2000, 8(6), 434-443.
141. Revesz, L.; Di Padova, F.E.; Buhl, T.; Feifel, R.; Gram, H.; Hiestand, P.; Manning, U.; Zimmerlin, A.G. SAR of 4- hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors. Bioorg. Med. Chem. Lett., 2000, 10(11), 1261-1264.
142. Kim, S.W.; Yu, Y.M.; Piao, C.S.; Kim, J.B.; Lee, J.K. Inhibition of delayed induction of p38 mitogen-activated protein kinase attenuates kainic acid-induced neuronal loss in the hippocampus. Brain Res., 2004, 1007(1-2), 188-191.
143. Jiang, W.; Van Cleemput, J.; Sheerin, A. H.; Ji, S. P.; Zhang, Y.; Saucier, D.M.; Corcoran, M. E.; Zhang, X. Involvement of extracellular regulated kinase and p38 kinase in hippocampal seizure tolerance. J. Neurosci. Res., 2005, 81(4), 581-588.
144. Nishimura, M.; Sugino, T.; Nozaki, K.; Takagi, Y.; Hattori, I.; Hayashi, J.; Hashimoto, N.; Moriguchi, T.; Nishida, E. Activation of p38 kinase in the gerbil hippocampus showing ischemic tolerance. J. Cereb. Blood Flow Metab., 2003, 23(9), 1052-1059.
145. Piao, C. S.; Kim, J. B.; Han, P. L.; Lee, J. K. Administration of the p38 MAPK inhibitor SB203580 affords brain protection with a wide therapeutic window against focal ischemic insult. J. Neurosci. Res., 2003, 73(4), 537-544.
146. Sugino, T.; Nozaki, K.; Takagi, Y.; Hattori, I.; Hashimoto, N.; Moriguchi, T.; Nishida, E. Activation of mitogen-activated protein kinases after transient forebrain ischemia in gerbil hippocampus. J. Neurosci., 2000, 20(12), 4506-4514.
147. Schafers, M.; Svensson, C.I.; Sommer, C.; Sorkin, L.S. Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J. Neurosci., 2003, 23(7), 2517-2521.
148. Jin, S. X.; Zhuang, Z.Y.; Woolf, C. J.; Ji, R.R. p38 mitogenactivated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J. Neurosci., 2003, 23(10), 4017-4022.
149. Obata, K.; Yamanaka, H.; Dai, Y.; Mizushima, T.; Fukuoka, T.; Tokunaga, A.; Noguchi, K. Differential activation of MAPK in injured and uninjured DRG neurons following chronic constriction injury of the sciatic nerve in rats. Eur. J. Neurosci., 2004, 20(11), 2881-2895.
150. Xu, J.T.; Xin, W.J.; Wei, X.H.; Wu, C.Y.; Ge, Y.X.; Liu, Y.L.; Zang, Y.; Zhang, T.; Li, Y.Y.; Liu, X.G. p38 activation in uninjured primary afferent neurons and in spinal microglia contributes to the development of neuropathic pain induced by selective motor fiber injury. Exp. Neurol., 2007, 204(1), 355-365.
151. Terayama, R.; Omura, S.; Fujisawa, N.; Yamaai, T.; Ichikawa, H.; Sugimoto, T. Activation of microglia and p38 mitogen-activated protein kinase in the dorsal column nucleus contributes to tactile allodynia following peripheral nerve injury. Neuroscience, 2008, 153(4), 1245-1255.
152. Munoz, L.; Ranaivo, H.R.; Roy, S.M.; Hu, W.; Craft, J.M.; McNamara, L.K.; Chico, L.W.; Van Eldik, L.J.; Watterson, D.M. A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J. Neuroinflamm., 2007, 4, 21.
153. Legos, J. J.; Erhardt, J. A.; White, R. F.; Lenhard, S. C.; Chandra, S.; Parsons, A. A.; Tuma, R. F.; Barone, F. C. SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia. Brain Res., 2001, 892(1), 70-77.
154. Jin, X.; Gereau, R.W.T. Acute p38-mediated modulation of tetrodotoxin- resistant sodium channels in mouse sensory neurons by tumor necrosis factor-alpha. J. Neurosci., 2006, 26(1), 246-255.
155. Milligan, E.D.; Twining, C.; Chacur, M.; Biedenkapp, J.; O'Connor, K.; Poole, S.; Tracey, K.; Martin, D.; Maier, S.F.; Watkins, L.R. Spinal glia and proinflammatory cytokines mediate mirrorimage neuropathic pain in rats. J. Neurosci., 2003, 23(3), 1026-1040.
156. Lee, M. R.; Dominguez, C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr. Med. Chem., 2005, 12(25), 2979-2994.
157. Dominguez, C.; Powers, D. A.; Tamayo, N. p38 MAP kinase inhibitors: many are made, but few are chosen. Curr. Opin. Drug Discov. Devel., 2005, 8(4), 421-430.
158. Sayle, R.A.; Milner-White, E.J. RASMOL: biomolecular graphics for all. Trends Biochem. Sci., 1995, 20(9), 374-376.